Cell and gene therapies for refractory epilepsy

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Refractory epilepsy affects up to 35% of patients with partial epilepsy, with limited treatment options.
• Conventional antiepileptic drugs often fail to address the underlying disease process.
• Novel therapeutic strategies are crucial for managing drug-resistant epilepsy.

Purpose of the Study:

• To review recent advancements in cell and gene-based therapies for refractory epilepsy.
• To explore the potential of endogenous anticonvulsant compounds like GABA, adenosine, galanin, and neuropeptide Y.
• To evaluate the preclinical efficacy and challenges of these novel therapeutic approaches.

Main Methods:

• Review of preclinical studies on cell transplantation and gene therapy for epilepsy.
• Analysis of neurochemical rationales for using GABA, adenosine, galanin, and neuropeptide Y.
• Critical evaluation of focal delivery strategies versus systemic administration.

Main Results:

• Cell and gene therapies offer targeted delivery of anticonvulsant compounds, potentially overcoming limitations of systemic drug administration.
• Ex vivo gene therapy (cell transplantation) and in vivo gene therapy (in situ production) show promise.
• Focal application enhances specificity to epileptogenic networks and may reduce side effects.

Conclusions:

• Cell and gene-based neuropharmacology presents a promising avenue for treating refractory epilepsy.
• Further research is needed to address long-term efficacy, safety, and validation in relevant animal models before clinical application.
• Targeted delivery of endogenous anticonvulsants holds potential for improved epilepsy management.